DDInter839 DDInter927
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Goserelin {u} (Compound) resembles {v} (Compound) Pentagastrin
Goserelin {u} (Compound) resembles {v} (Compound) Cetrorelix
Goserelin {u} (Compound) treats {v} (Disease) breast cancer
Goserelin {u} (Compound) binds {v} (Gene) LHCGR
Goserelin {u} (Compound) upregulates {v} (Gene) SPAG4
Goserelin {u} (Compound) is included by {v} (Pharmacologic Class) Gonadotropin Releasing Hormone Receptor Agonists
Goserelin {u} (Compound) causes {v} (Side Effect) Reaction aggravation
Goserelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Goserelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Goserelin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Goserelin (Compound) resembles Pentagastrin (Compound)
Goserelin (Compound) resembles Cetrorelix (Compound)
Goserelin (Compound) treats breast cancer (Disease)
Goserelin (Compound) binds LHCGR (Gene)
Goserelin (Compound) upregulates SPAG4 (Gene)
Goserelin (Compound) is included by Gonadotropin Releasing Hormone Receptor Agonists (Pharmacologic Class)
Goserelin (Compound) causes Reaction aggravation (Side Effect)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Goserelin may lead to a major life threatening interaction when taken with Dolasetron